Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
Publishing timestamp: 2023-11-02 16:30:12
Summary
Eli Lilly has announced that the supply of its diabetes drug Mounjaro has improved in the U.S. after months of shortages. However, the company is still working to increase production capacity due to increased demand, especially for its off-label ability to cause weight loss. The article also mentions that U.S. regulators could potentially approve the drug for weight loss, further increasing demand. Eli Lilly's rival, Novo Nordisk, is also facing supply constraints for its diabetes drug Ozempic and obesity treatment Wegovy.
Sentiment: MIXED
Keywords: business news, eli lilly and co, novo nordisk a/s, biotech and pharmaceuticals, health care industry, pharmaceuticals, biotechnology, breaking news, pfizer inc, business,
Source: https://www.cnbc.com/2023/11/02/eli-lilly-diabetes-drug-mounjaro-supply-improves-in-us.html